News | Atrial Fibrillation | April 20, 2016

Rate, Rhythm Control Equally Effective in Post-Operative Atrial Fibrillation

Study finds both strategies acceptable in stable patients following cardiac surgery

post-operative atrial fibrillation, AFib, heart rate, rhythm control, ACC.16

April 20, 2016 — In the first large randomized trial to directly compare two approaches to preventing atrial fibrillation following heart surgery, controlling heart rate and controlling heart rhythm performed equally well. The research was presented at the American College of Cardiology’s 65th Annual Scientific Session, April 2-4 in Chicago.

A third to half of the patients who undergo either coronary artery bypass surgery or heart valve replacement surgery every year in the United States will develop atrial fibrillation, or AFib, an abnormal heart rhythm. Compared with patients who do not get AFib, those who develop the abnormal heart rhythm during the first 60 days after surgery have longer hospital stays, an elevated risk of stroke, other adverse events and complications, and a higher risk of death.

“For the primary endpoint of total number of days in the hospital from the date that therapy was started until 60 days after beginning treatment, we found that for the stable post-surgical patient, rate control and rhythm control are both acceptable strategies,” said Marc Gillinov, M.D., a cardiac surgeon at the Cleveland Clinic and lead author of the study. “This is important because it means that the choice of strategy can be determined by what is clinically preferable for the individual patient.”

It is estimated that treating post-operative AFib adds about $1 billion a year to the nation’s healthcare costs, Gillinov said. “We do not have a reliable, generally accepted way of preventing AFib in this patient population, and there had never been a large trial to determine whether one of the two ways of treating it was better than the other,” he said. This trial was designed to fill that gap.

The study was conducted at 23 academic medical centers in the United States and Canada. It enrolled 2,109 patients who were about to undergo either bypass or valve replacement/valve repair surgery. Patients who had either one episode of AFib lasting more than 60 minutes or more than one AFib episode during the first seven days after surgery were eligible to be randomly assigned to one of the two study treatments. The 523 patients who developed post-operative Afib were randomly assigned to either heart rate control treatment with beta blockers or heart rhythm control treatment with the drug amiodarone with or without electrical cardioversion to restore normal rhythm. All patients who had recurrent AFib or whose AFib lasted more than 48 hours were considered for treatment with the blood-thinning drug warfarin. Patients were 68 years old on average and 75 percent were male. The follow-up period was 60 days after surgery.

At the end of the follow-up period lengths of stay in the hospital, the study’s primary endpoint, were almost identical in the two groups: 5.1 days for the rate control group, 5.0 days for the rhythm control group. The proportion of patients who were AFib-free at 60 days, the secondary endpoint, was also similar in both groups: 93.8 percent for the rate control group, 97.9 percent for the rhythm control group.

Although the differences between the two groups were not statistically significant, there were some clinical differences, Gillinov said. Patients in the rhythm control group were slightly more likely to be free of Afib at 60 days but more likely to have adverse effects from amiodarone. Patients in the rate control group had lower rates of treatment side effects but were slightly more likely to still have AFib at the end of the follow-up period.

“We have shown that post-operative AFib will resolve in more than 90 percent of patients who are treated with either rate control or rhythm control,” Gillinov said. “Patients and physicians now have the option to choose the strategy that’s best for each individual patient.”

In selecting a treatment strategy, physicians need to consider the potential toxicity of amiodarone and the possible need for cardioversion, which is performed under general anesthesia, he said.

The study’s main limitation was that about 25 percent of the patients in each group did not complete their assigned treatment and were switched to the other treatment group, Gillinov said. The study also did not have the statistical power to detect any differences in outcomes between patients who received warfarin and those who did not. This question may be the focus of a follow-up study, he said.

The trial was conducted by the Cardiothoracic Surgical Trials Network, which is funded by the National Heart, Lung and Blood Institute, the National Institute for Neurological Disorders and Stroke and the Canadian Institutes for Health Research.

This study was published online in the New England Journal of Medicine simultaneously with the presentation.

For more information: www.nejm.org

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init